Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Boyd Hanson"'
Publikováno v:
Clinical Therapeutics. 37(7):1555-1563
Purpose Amifampridine (3,4-diaminopyridine) has been approved in the European Union for the treatment of Lambert-Eaton myasthenic syndrome. Amifampridine has a narrow therapeutic index, and supratherapeutic exposure has been associated with dose-depe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba24872c3ef05ce93a8f15db3793b969
Autor:
Charles A. O'Neill, Laurie S. Tsuruda, Marvin R. Garovoy, Boyd Hanson, Peter E. Haroldsen, Donald G. Musson, Huiyu Zhou
Publikováno v:
Pharmacology Research & Perspectives
The clinical use of amifampridine phosphate for neuromuscular junction disorders is increasing. The metabolism of amifampridine occurs via polymorphic aryl N-acetyltransferase (NAT), yet its pharmacokinetic (PK) and safety profiles, as influenced by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b75b187a6860b4b832c9582eff02e99
https://doi.org/10.1002/prp2.99
https://doi.org/10.1002/prp2.99